Daratumumab monotherapy versus bortezomib-based regimen in patients with biopsy-proven renal AL amyloidosis ineligible for Bone Marrow Transplant
Nephrology Dialysis Transplantation · 20.05.2026
DOI: 10.1093/ndt/gfag117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 20.05.2026. Verfasst von Roccatello Dario und 7 weiteren Autor:innen. Beteiligte Einrichtung: University Center of Excellence (ERK-Net, ERN-Reconnet and ERN-RITA Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and R…. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Piedmont and Aosta Valley.
Abstract (Originalsprache)
Background
Bortezomib-based regimens have long represented the standard option for Systemic light-chain (AL) amyloidosis amyloidosis, whereas daratumumab has recently emerged as a promising alternative. We compared two consecutive single-center cohorts of frail, non-transplant-eligible patients treated with either bortezomib-based therapy or daratumumab monotherapy, assessing clinical and renal outcomes.
Methods
Thirty-one patients with renal AL amyloidosis were included: 17 received bortezomib-based regimens (historical cohort) and 14 received daratumumab monotherapy (prospective cohort). All had biopsy-confirmed renal amyloid deposition and were transplant-ineligible. Hematologic and organ responses followed International Society of Amyloidosis criteria.
Results
Baseline characteristics were similar between cohorts. Hematologic response rates were 57.1% with bortezomib versus 92.8% with daratumumab (P = .03), with complete responses in 28.6% and 57.1%, respectively. Renal response occurred in 35% of bortezomib-treated patients versus 71.4% with daratumumab (P = .04). Proteinuria declined by 76% in bortezomib responders and 72% in daratumumab responders, with stable creatinine in both groups. Among patients achieving dual hematologic and renal responses, 12-month survival was 100% in the daratumumab cohort versus 71% in the historical group. At last follow-up, renal survival was 67% versus 86%, and overall survival 47% versus 79% (P = .08). Major infections occurred in 18% and 14%, respectively. Repeat biopsies showed stabilization or regression of amyloid in 62% of daratumumab-treated versus 20% of historical cases.
Conclusions
In frail, Autologous Stem Cell Transplant (ASCT)-ineligible patients with biopsy-proven renal AL amyloidosis, daratumumab monotherapy yielded higher hematologic and renal response rates compared with bortezomib-based regimens. These findings support early anti-CD38 therapy as a potential strategy to improve renal preservation and survival, warranting confirmation in multicenter trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Center of Excellence (ERK-Net, ERN-Reconnet and ERN-RITA Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network…
- Division of Pathology, Città Della Salute e Della Scienza Hospital and University of Turin, Turin, Italy.
ORCID-Profile: Sciascia Savino
Förderung
- Piedmont and Aosta Valley
Zitieren
APA
Dario, R., Savino, S., Barreca, A., Gianluca, R., Giulio, D. V., Daniela, R., Elena, R., & Roberta, F. (2026). Daratumumab monotherapy versus bortezomib-based regimen in patients with biopsy-proven renal AL amyloidosis ineligible for Bone Marrow Transplant. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag117
Vancouver
Dario R, Savino S, Barreca A, Gianluca R, Giulio DV, Daniela R, et al. Daratumumab monotherapy versus bortezomib-based regimen in patients with biopsy-proven renal AL amyloidosis ineligible for Bone Marrow Transplant. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag117
BibTeX
@article{Dario2026,
author = {Dario, Roccatello and Savino, Sciascia and Barreca, Antonella and Gianluca, Rabajoli and Giulio, Del Vecchio and Daniela, Rossi and Elena, Rubini and Roberta, Fenoglio},
title = {Daratumumab monotherapy versus bortezomib-based regimen in patients with biopsy-proven renal AL amyloidosis ineligible for Bone Marrow Transplant},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag117}
}
EUVIMED